AT/RT vs. Brain |
Brain | AT/RT | Type | AllPCG | DiffPCG | CancerG |
Yes | No | I | 66,125 | 18,651 | 2629 |
No | Yes | II | 3059 | 232 | 138 |
Positive | Nagetive | III | 16 | 4 | 2 |
Nagetive | Positive | IV | 36 | 2 | 4 |
KRT vs. Kidney |
Kidney | KRT | Type | AllPCG | DiffPCG | CancerG |
Yes | No | I | 16,408 | 6259 | 675 |
No | Yes | II | 28,350 | 7371 | 1284 |
Positive | Nagetive | III | 260 | 100 | 12 |
Nagetive | Positive | IV | 157 | 35 | 5 |
AT/RT vs. KRT |
AT/RT | KRT | Type | AllPCG | DiffPCG | CancerG |
Yes | No | I | 5543 | 776 | 263 |
No | Yes | II | 45,245 | 6908 | 1742 |
Positive | Nagetive | III | 53 | 2 | 5 |
Nagetive | Positive | IV | 21 | 3 | 1 |
- Co-expressed pair were classified into four types, based on presence and type of regulation of the co-expression in the three sets of comparisons, namely (A) AT/RT vs normal brain samples, (B) KRT vs normal kidney samples, and (C) AT/RT vs KRT samples. Type I: co-expressed pairs that were present in AT/RT (A), KRT (B), and AT/RT (C), and absent in normal brain samples (A), normal kidney samples (B), and KRT(C). Type II: co-expressed pairs that were absent in AT/RT (A), KRT (B), and AT/RT (C), and was present in the corresponding control samples. Type III: co-expression pairs that were positively co-expressed in AT/RT (A), KRT (B), and AT/RT (C) and negatively co-expressed in the corresponding control samples. Type IV: co-expression pairs that were negatively co-expressed in AT/RT (A), KRT (B), and AT/RT (C) and positively co-expressed in the corresponding control samples